PDB Short entry for 1WZ9 HEADER SIGNALING PROTEIN 03-MAR-05 1WZ9 TITLE THE 2.1 A STRUCTURE OF A TUMOUR SUPPRESSING SERPIN COMPND MOL_ID: 1; COMPND 2 MOLECULE: MASPIN PRECURSOR; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: PROTEASE INHIBITOR 5; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: SERPINB5; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PRSETC KEYWDS MASPIN, SERPIN, TUMOR SUPPRESSOR, SERPINB5, SIGNALING PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR R.H.LAW,J.A.IRVING,A.M.BUCKLE,K.RUZYLA,M.BUZZA,T.A.BASHTANNYK- AUTHOR 2 PUHALOVICH,T.C.BEDDOE,N.KIM,D.M.WORRALL,S.P.BOTTOMLEY,P.I.BIRD, AUTHOR 3 J.ROSSJOHN,J.C.WHISSTOCK REVDAT 4 11-OCT-17 1WZ9 1 REMARK REVDAT 3 24-FEB-09 1WZ9 1 VERSN REVDAT 2 21-JUN-05 1WZ9 1 JRNL REVDAT 1 15-MAR-05 1WZ9 0 JRNL AUTH R.H.LAW,J.A.IRVING,A.M.BUCKLE,K.RUZYLA,M.BUZZA, JRNL AUTH 2 T.A.BASHTANNYK-PUHALOVICH,T.C.BEDDOE,K.NGUYEN,D.M.WORRALL, JRNL AUTH 3 S.P.BOTTOMLEY,P.I.BIRD,J.ROSSJOHN,J.C.WHISSTOCK JRNL TITL THE HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN TUMOR JRNL TITL 2 SUPPRESSOR MASPIN REVEALS A NOVEL CONFORMATIONAL SWITCH IN JRNL TITL 3 THE G-HELIX. JRNL REF J.BIOL.CHEM. V. 280 22356 2005 JRNL REFN ISSN 0021-9258 JRNL PMID 15760906 JRNL DOI 10.1074/JBC.M412043200 REMARK 2 REMARK 2 RESOLUTION. 2.10 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0005 REMARK 3 AUTHORS : MURSHUDOV,VAGIN,DODSON REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.10 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 78.57 REMARK 3 DATA CUTOFF (SIGMA(F)) : 139.22 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.6 REMARK 3 NUMBER OF REFLECTIONS : 40352 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.207 REMARK 3 R VALUE (WORKING SET) : 0.205 REMARK 3 FREE R VALUE : 0.249 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 2136 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.10 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.16 REMARK 3 REFLECTION IN BIN (WORKING SET) : 2908 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 98.68 REMARK 3 BIN R VALUE (WORKING SET) : 0.2630 REMARK 3 BIN FREE R VALUE SET COUNT : 159 REMARK 3 BIN FREE R VALUE : 0.3100 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 5523 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 5 REMARK 3 SOLVENT ATOMS : 201 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 40.63 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.42000 REMARK 3 B22 (A**2) : -0.23000 REMARK 3 B33 (A**2) : -0.19000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.252 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.201 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.157 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 11.953 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.953 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.932 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 5628 ; 0.008 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 7614 ; 1.152 ; 1.971 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 718 ; 5.520 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 226 ;38.427 ;26.150 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 943 ;15.601 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 6 ;18.406 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 891 ; 0.076 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 4134 ; 0.003 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 2512 ; 0.190 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 3840 ; 0.300 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 273 ; 0.128 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 27 ; 0.175 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 6 ; 0.135 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 3721 ; 1.191 ; 3.000 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 5815 ; 2.039 ; 5.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 2125 ; 3.340 ; 7.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 1799 ; 4.843 ;10.000 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL WITH MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS REMARK 4 REMARK 4 1WZ9 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 04-MAR-05. REMARK 100 THE DEPOSITION ID IS D_1000024180. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 02-OCT-04 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.3 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : GRAPHITE REMARK 200 OPTICS : OSMIC MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IV REMARK 200 INTENSITY-INTEGRATION SOFTWARE : R-AXIS REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 42714 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.100 REMARK 200 RESOLUTION RANGE LOW (A) : 78.600 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 200 DATA REDUNDANCY : 36.80 REMARK 200 R MERGE (I) : 0.04500 REMARK 200 R SYM (I) : 0.04500 REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 22.2000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: 1XU8 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 42.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.10 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.1M BISTRIS, 2.9M (NH4)2SO4, PH 8.3, REMARK 280 VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 295K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 27.05750 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 69.61250 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 47.52350 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 69.61250 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 27.05750 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 47.52350 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 331 REMARK 465 ASP A 332 REMARK 465 SER A 333 REMARK 465 ILE A 334 REMARK 465 GLU A 335 REMARK 465 VAL A 336 REMARK 465 PRO A 337 REMARK 465 GLY A 338 REMARK 465 ALA A 339 REMARK 465 ARG A 340 REMARK 465 ILE A 341 REMARK 465 LEU A 342 REMARK 465 ASP B 150 REMARK 465 ASN B 151 REMARK 465 GLU B 237 REMARK 465 ASP B 238 REMARK 465 GLU B 239 REMARK 465 SER B 240 REMARK 465 ILE B 334 REMARK 465 GLU B 335 REMARK 465 VAL B 336 REMARK 465 PRO B 337 REMARK 465 GLY B 338 REMARK 465 ALA B 339 REMARK 465 ARG B 340 REMARK 465 ILE B 341 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LYS A 22 CD CE NZ REMARK 470 GLU A 61 CG CD OE1 OE2 REMARK 470 LYS A 64 CG CD CE NZ REMARK 470 LYS A 96 CD CE NZ REMARK 470 GLU A 103 CD OE1 OE2 REMARK 470 LYS A 109 CD CE NZ REMARK 470 ARG A 110 CD NE CZ NH1 NH2 REMARK 470 LYS A 114 CD CE NZ REMARK 470 LYS A 122 CG CD CE NZ REMARK 470 LYS A 124 CD CE NZ REMARK 470 LYS A 129 CE NZ REMARK 470 ASP A 150 CG OD1 OD2 REMARK 470 ASN A 151 CG OD1 ND2 REMARK 470 LYS A 158 CE NZ REMARK 470 LYS A 174 CD CE NZ REMARK 470 LYS A 181 CE NZ REMARK 470 ILE A 212 CG1 CG2 CD1 REMARK 470 LYS A 245 CE NZ REMARK 470 LYS A 268 CG CD CE NZ REMARK 470 LYS A 270 CD CE NZ REMARK 470 LYS A 294 CG CD CE NZ REMARK 470 ILE A 296 CG1 CG2 CD1 REMARK 470 ASP A 300 CG OD1 OD2 REMARK 470 GLN A 343 CG CD OE1 NE2 REMARK 470 HIS A 344 CG ND1 CD2 CE1 NE2 REMARK 470 LYS A 345 CD CE NZ REMARK 470 LYS A 362 CE NZ REMARK 470 ARG A 364 CD NE CZ NH1 NH2 REMARK 470 ASP B 2 CG OD1 OD2 REMARK 470 CME B 20 SD CE CZ OH REMARK 470 GLU B 21 CG CD OE1 OE2 REMARK 470 GLU B 23 OE1 OE2 REMARK 470 ASN B 62 OD1 ND2 REMARK 470 LYS B 64 CG CD CE NZ REMARK 470 SER B 97 OG REMARK 470 LEU B 100 CG CD1 CD2 REMARK 470 GLU B 103 CG CD OE1 OE2 REMARK 470 LYS B 109 CG CD CE NZ REMARK 470 ARG B 110 CG CD NE CZ NH1 NH2 REMARK 470 LYS B 114 CG CD CE NZ REMARK 470 LYS B 122 CG CD CE NZ REMARK 470 LYS B 124 CG CD CE NZ REMARK 470 GLU B 126 CG CD OE1 OE2 REMARK 470 GLU B 127 CG CD OE1 OE2 REMARK 470 GLN B 131 CG CD OE1 NE2 REMARK 470 ASN B 146 CG OD1 ND2 REMARK 470 VAL B 153 CG1 CG2 REMARK 470 GLU B 179 OE1 OE2 REMARK 470 LYS B 181 CG CD CE NZ REMARK 470 LYS B 189 CG CD CE NZ REMARK 470 ASP B 210 CG OD1 OD2 REMARK 470 CME B 214 SD CE CZ OH REMARK 470 LYS B 234 CD CE NZ REMARK 470 ASP B 235 CG OD1 OD2 REMARK 470 VAL B 236 CG1 CG2 REMARK 470 THR B 241 OG1 CG2 REMARK 470 GLU B 244 CG CD OE1 OE2 REMARK 470 LYS B 248 CG CD CE NZ REMARK 470 GLU B 253 CD OE1 OE2 REMARK 470 LYS B 268 CG CD CE NZ REMARK 470 LYS B 270 CG CD CE NZ REMARK 470 MET B 281 CG SD CE REMARK 470 LYS B 294 CG CD CE NZ REMARK 470 GLU B 309 CG CD OE1 OE2 REMARK 470 LYS B 311 CG CD CE NZ REMARK 470 LYS B 321 CD CE NZ REMARK 470 CME B 323 SD CE CZ OH REMARK 470 ASP B 332 CG OD1 OD2 REMARK 470 SER B 333 OG REMARK 470 LEU B 342 CG CD1 CD2 REMARK 470 GLN B 343 CG CD OE1 NE2 REMARK 470 LYS B 345 CG CD CE NZ REMARK 470 ARG B 364 CD NE CZ NH1 NH2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 65 72.26 48.74 REMARK 500 ASN A 99 66.73 39.58 REMARK 500 LYS A 114 -5.93 74.23 REMARK 500 ASP A 120 77.54 -109.31 REMARK 500 LYS A 124 55.54 -140.91 REMARK 500 ASN A 188 -161.45 -167.10 REMARK 500 ASN B 99 72.22 45.15 REMARK 500 LYS B 114 -2.41 70.32 REMARK 500 LYS B 124 60.96 -115.87 REMARK 500 LYS B 294 -62.55 -131.43 REMARK 500 ASP B 332 -149.77 -85.45 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 1001 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1XU8 RELATED DB: PDB REMARK 900 THE 2.8 A STRUCTURE OF A TUMOUR SUPRESSING SERPIN DBREF 1WZ9 A 1 375 UNP P36952 MASP_HUMAN 1 375 DBREF 1WZ9 B 1 375 UNP P36952 MASP_HUMAN 1 375 SEQADV 1WZ9 CME A 20 UNP P36952 CYS 20 MODIFIED RESIDUE SEQADV 1WZ9 VAL A 66 UNP P36952 ILE 66 SEE REMARK 999 SEQADV 1WZ9 CME A 183 UNP P36952 CYS 183 MODIFIED RESIDUE SEQADV 1WZ9 CME A 205 UNP P36952 CYS 205 MODIFIED RESIDUE SEQADV 1WZ9 CME A 214 UNP P36952 CYS 214 MODIFIED RESIDUE SEQADV 1WZ9 CME A 323 UNP P36952 CYS 323 MODIFIED RESIDUE SEQADV 1WZ9 CME A 373 UNP P36952 CYS 373 MODIFIED RESIDUE SEQADV 1WZ9 CME B 20 UNP P36952 CYS 20 MODIFIED RESIDUE SEQADV 1WZ9 VAL B 66 UNP P36952 ILE 66 SEE REMARK 999 SEQADV 1WZ9 CME B 183 UNP P36952 CYS 183 MODIFIED RESIDUE SEQADV 1WZ9 CME B 205 UNP P36952 CYS 205 MODIFIED RESIDUE SEQADV 1WZ9 CME B 214 UNP P36952 CYS 214 MODIFIED RESIDUE SEQADV 1WZ9 CME B 323 UNP P36952 CYS 323 MODIFIED RESIDUE SEQADV 1WZ9 CME B 373 UNP P36952 CYS 373 MODIFIED RESIDUE SEQRES 1 A 375 MET ASP ALA LEU GLN LEU ALA ASN SER ALA PHE ALA VAL SEQRES 2 A 375 ASP LEU PHE LYS GLN LEU CME GLU LYS GLU PRO LEU GLY SEQRES 3 A 375 ASN VAL LEU PHE SER PRO ILE CYS LEU SER THR SER LEU SEQRES 4 A 375 SER LEU ALA GLN VAL GLY ALA LYS GLY ASP THR ALA ASN SEQRES 5 A 375 GLU ILE GLY GLN VAL LEU HIS PHE GLU ASN VAL LYS ASP SEQRES 6 A 375 VAL PRO PHE GLY PHE GLN THR VAL THR SER ASP VAL ASN SEQRES 7 A 375 LYS LEU SER SER PHE TYR SER LEU LYS LEU ILE LYS ARG SEQRES 8 A 375 LEU TYR VAL ASP LYS SER LEU ASN LEU SER THR GLU PHE SEQRES 9 A 375 ILE SER SER THR LYS ARG PRO TYR ALA LYS GLU LEU GLU SEQRES 10 A 375 THR VAL ASP PHE LYS ASP LYS LEU GLU GLU THR LYS GLY SEQRES 11 A 375 GLN ILE ASN ASN SER ILE LYS ASP LEU THR ASP GLY HIS SEQRES 12 A 375 PHE GLU ASN ILE LEU ALA ASP ASN SER VAL ASN ASP GLN SEQRES 13 A 375 THR LYS ILE LEU VAL VAL ASN ALA ALA TYR PHE VAL GLY SEQRES 14 A 375 LYS TRP MET LYS LYS PHE PRO GLU SER GLU THR LYS GLU SEQRES 15 A 375 CME PRO PHE ARG LEU ASN LYS THR ASP THR LYS PRO VAL SEQRES 16 A 375 GLN MET MET ASN MET GLU ALA THR PHE CME MET GLY ASN SEQRES 17 A 375 ILE ASP SER ILE ASN CME LYS ILE ILE GLU LEU PRO PHE SEQRES 18 A 375 GLN ASN LYS HIS LEU SER MET PHE ILE LEU LEU PRO LYS SEQRES 19 A 375 ASP VAL GLU ASP GLU SER THR GLY LEU GLU LYS ILE GLU SEQRES 20 A 375 LYS GLN LEU ASN SER GLU SER LEU SER GLN TRP THR ASN SEQRES 21 A 375 PRO SER THR MET ALA ASN ALA LYS VAL LYS LEU SER ILE SEQRES 22 A 375 PRO LYS PHE LYS VAL GLU LYS MET ILE ASP PRO LYS ALA SEQRES 23 A 375 CYS LEU GLU ASN LEU GLY LEU LYS HIS ILE PHE SER GLU SEQRES 24 A 375 ASP THR SER ASP PHE SER GLY MET SER GLU THR LYS GLY SEQRES 25 A 375 VAL ALA LEU SER ASN VAL ILE HIS LYS VAL CME LEU GLU SEQRES 26 A 375 ILE THR GLU ASP GLY GLY ASP SER ILE GLU VAL PRO GLY SEQRES 27 A 375 ALA ARG ILE LEU GLN HIS LYS ASP GLU LEU ASN ALA ASP SEQRES 28 A 375 HIS PRO PHE ILE TYR ILE ILE ARG HIS ASN LYS THR ARG SEQRES 29 A 375 ASN ILE ILE PHE PHE GLY LYS PHE CME SER PRO SEQRES 1 B 375 MET ASP ALA LEU GLN LEU ALA ASN SER ALA PHE ALA VAL SEQRES 2 B 375 ASP LEU PHE LYS GLN LEU CME GLU LYS GLU PRO LEU GLY SEQRES 3 B 375 ASN VAL LEU PHE SER PRO ILE CYS LEU SER THR SER LEU SEQRES 4 B 375 SER LEU ALA GLN VAL GLY ALA LYS GLY ASP THR ALA ASN SEQRES 5 B 375 GLU ILE GLY GLN VAL LEU HIS PHE GLU ASN VAL LYS ASP SEQRES 6 B 375 VAL PRO PHE GLY PHE GLN THR VAL THR SER ASP VAL ASN SEQRES 7 B 375 LYS LEU SER SER PHE TYR SER LEU LYS LEU ILE LYS ARG SEQRES 8 B 375 LEU TYR VAL ASP LYS SER LEU ASN LEU SER THR GLU PHE SEQRES 9 B 375 ILE SER SER THR LYS ARG PRO TYR ALA LYS GLU LEU GLU SEQRES 10 B 375 THR VAL ASP PHE LYS ASP LYS LEU GLU GLU THR LYS GLY SEQRES 11 B 375 GLN ILE ASN ASN SER ILE LYS ASP LEU THR ASP GLY HIS SEQRES 12 B 375 PHE GLU ASN ILE LEU ALA ASP ASN SER VAL ASN ASP GLN SEQRES 13 B 375 THR LYS ILE LEU VAL VAL ASN ALA ALA TYR PHE VAL GLY SEQRES 14 B 375 LYS TRP MET LYS LYS PHE PRO GLU SER GLU THR LYS GLU SEQRES 15 B 375 CME PRO PHE ARG LEU ASN LYS THR ASP THR LYS PRO VAL SEQRES 16 B 375 GLN MET MET ASN MET GLU ALA THR PHE CME MET GLY ASN SEQRES 17 B 375 ILE ASP SER ILE ASN CME LYS ILE ILE GLU LEU PRO PHE SEQRES 18 B 375 GLN ASN LYS HIS LEU SER MET PHE ILE LEU LEU PRO LYS SEQRES 19 B 375 ASP VAL GLU ASP GLU SER THR GLY LEU GLU LYS ILE GLU SEQRES 20 B 375 LYS GLN LEU ASN SER GLU SER LEU SER GLN TRP THR ASN SEQRES 21 B 375 PRO SER THR MET ALA ASN ALA LYS VAL LYS LEU SER ILE SEQRES 22 B 375 PRO LYS PHE LYS VAL GLU LYS MET ILE ASP PRO LYS ALA SEQRES 23 B 375 CYS LEU GLU ASN LEU GLY LEU LYS HIS ILE PHE SER GLU SEQRES 24 B 375 ASP THR SER ASP PHE SER GLY MET SER GLU THR LYS GLY SEQRES 25 B 375 VAL ALA LEU SER ASN VAL ILE HIS LYS VAL CME LEU GLU SEQRES 26 B 375 ILE THR GLU ASP GLY GLY ASP SER ILE GLU VAL PRO GLY SEQRES 27 B 375 ALA ARG ILE LEU GLN HIS LYS ASP GLU LEU ASN ALA ASP SEQRES 28 B 375 HIS PRO PHE ILE TYR ILE ILE ARG HIS ASN LYS THR ARG SEQRES 29 B 375 ASN ILE ILE PHE PHE GLY LYS PHE CME SER PRO MODRES 1WZ9 CME A 20 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 1WZ9 CME A 183 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 1WZ9 CME A 205 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 1WZ9 CME A 214 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 1WZ9 CME A 323 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 1WZ9 CME A 373 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 1WZ9 CME B 20 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 1WZ9 CME B 183 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 1WZ9 CME B 205 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 1WZ9 CME B 214 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 1WZ9 CME B 323 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 1WZ9 CME B 373 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE HET CME A 20 10 HET CME A 183 10 HET CME A 205 10 HET CME A 214 10 HET CME A 323 10 HET CME A 373 10 HET CME B 20 6 HET CME B 183 10 HET CME B 205 10 HET CME B 214 6 HET CME B 323 6 HET CME B 373 10 HET SO4 A1001 5 HETNAM CME S,S-(2-HYDROXYETHYL)THIOCYSTEINE HETNAM SO4 SULFATE ION FORMUL 1 CME 12(C5 H11 N O3 S2) FORMUL 3 SO4 O4 S 2- FORMUL 4 HOH *201(H2 O) HELIX 1 1 MET A 1 GLU A 23 1 23 HELIX 2 2 SER A 31 ALA A 46 1 16 HELIX 3 3 LYS A 47 LEU A 58 1 12 HELIX 4 4 ASP A 65 SER A 81 1 17 HELIX 5 5 SER A 97 ASN A 99 5 3 HELIX 6 6 SER A 101 LYS A 109 1 9 HELIX 7 7 LYS A 124 THR A 140 1 17 HELIX 8 8 PRO A 176 THR A 180 5 5 HELIX 9 9 GLN A 222 LYS A 224 5 3 HELIX 10 10 ASP A 238 LEU A 250 1 13 HELIX 11 11 ASN A 251 THR A 259 1 9 HELIX 12 12 ASN A 260 MET A 264 5 5 HELIX 13 13 ASP A 283 GLY A 292 1 10 HELIX 14 14 MET B 1 GLU B 23 1 23 HELIX 15 15 SER B 31 GLY B 45 1 15 HELIX 16 16 LYS B 47 LEU B 58 1 12 HELIX 17 17 HIS B 59 VAL B 63 5 5 HELIX 18 18 ASP B 65 SER B 81 1 17 HELIX 19 19 SER B 97 ASN B 99 5 3 HELIX 20 20 SER B 101 ARG B 110 1 10 HELIX 21 21 LYS B 124 THR B 140 1 17 HELIX 22 22 PRO B 176 THR B 180 5 5 HELIX 23 23 GLN B 222 LYS B 224 5 3 HELIX 24 24 GLY B 242 GLN B 249 1 8 HELIX 25 25 ASN B 251 THR B 259 1 9 HELIX 26 26 ASN B 260 MET B 264 5 5 HELIX 27 27 PRO B 284 GLY B 292 1 9 HELIX 28 28 LYS B 294 SER B 298 5 5 SHEET 1 A 7 LEU A 29 PHE A 30 0 SHEET 2 A 7 ASN A 365 PHE A 372 -1 O PHE A 369 N PHE A 30 SHEET 3 A 7 PHE A 354 HIS A 360 -1 N ILE A 358 O ILE A 367 SHEET 4 A 7 LEU A 226 PRO A 233 -1 N LEU A 231 O ILE A 355 SHEET 5 A 7 CME A 214 PRO A 220 -1 N LEU A 219 O MET A 228 SHEET 6 A 7 THR A 192 ILE A 209 -1 N GLY A 207 O ILE A 216 SHEET 7 A 7 LYS A 181 ARG A 186 -1 N PHE A 185 O LYS A 193 SHEET 1 B 8 LEU A 29 PHE A 30 0 SHEET 2 B 8 ASN A 365 PHE A 372 -1 O PHE A 369 N PHE A 30 SHEET 3 B 8 PHE A 354 HIS A 360 -1 N ILE A 358 O ILE A 367 SHEET 4 B 8 LEU A 226 PRO A 233 -1 N LEU A 231 O ILE A 355 SHEET 5 B 8 CME A 214 PRO A 220 -1 N LEU A 219 O MET A 228 SHEET 6 B 8 THR A 192 ILE A 209 -1 N GLY A 207 O ILE A 216 SHEET 7 B 8 ALA A 265 PRO A 274 -1 O ILE A 273 N MET A 198 SHEET 8 B 8 HIS A 344 ASN A 349 1 O LEU A 348 N SER A 272 SHEET 1 C 5 LEU A 116 VAL A 119 0 SHEET 2 C 5 SER A 85 ASP A 95 1 N LEU A 92 O GLU A 117 SHEET 3 C 5 ILE A 159 VAL A 168 -1 O ALA A 164 N ILE A 89 SHEET 4 C 5 LEU A 315 ILE A 326 1 O ILE A 319 N VAL A 161 SHEET 5 C 5 PHE A 276 ILE A 282 -1 N PHE A 276 O ILE A 326 SHEET 1 D 7 VAL B 28 PHE B 30 0 SHEET 2 D 7 ILE B 366 PHE B 372 -1 O LYS B 371 N VAL B 28 SHEET 3 D 7 PHE B 354 HIS B 360 -1 N PHE B 354 O PHE B 372 SHEET 4 D 7 LEU B 226 PRO B 233 -1 N PHE B 229 O ILE B 357 SHEET 5 D 7 CME B 214 PRO B 220 -1 N LEU B 219 O MET B 228 SHEET 6 D 7 THR B 192 ILE B 209 -1 N CME B 205 O GLU B 218 SHEET 7 D 7 LYS B 181 ARG B 186 -1 N LYS B 181 O MET B 197 SHEET 1 E 8 VAL B 28 PHE B 30 0 SHEET 2 E 8 ILE B 366 PHE B 372 -1 O LYS B 371 N VAL B 28 SHEET 3 E 8 PHE B 354 HIS B 360 -1 N PHE B 354 O PHE B 372 SHEET 4 E 8 LEU B 226 PRO B 233 -1 N PHE B 229 O ILE B 357 SHEET 5 E 8 CME B 214 PRO B 220 -1 N LEU B 219 O MET B 228 SHEET 6 E 8 THR B 192 ILE B 209 -1 N CME B 205 O GLU B 218 SHEET 7 E 8 ALA B 265 PRO B 274 -1 O ILE B 273 N MET B 198 SHEET 8 E 8 LYS B 345 ASN B 349 1 O LEU B 348 N SER B 272 SHEET 1 F 5 LEU B 116 VAL B 119 0 SHEET 2 F 5 SER B 85 ASP B 95 1 N VAL B 94 O GLU B 117 SHEET 3 F 5 ILE B 159 VAL B 168 -1 O ALA B 164 N ILE B 89 SHEET 4 F 5 LEU B 315 ILE B 326 1 O ILE B 319 N VAL B 161 SHEET 5 F 5 PHE B 276 ILE B 282 -1 N PHE B 276 O ILE B 326 LINK C LEU A 19 N CME A 20 1555 1555 1.34 LINK C CME A 20 N GLU A 21 1555 1555 1.33 LINK C GLU A 182 N CME A 183 1555 1555 1.33 LINK C CME A 183 N PRO A 184 1555 1555 1.34 LINK C PHE A 204 N CME A 205 1555 1555 1.33 LINK C CME A 205 N MET A 206 1555 1555 1.33 LINK C ASN A 213 N CME A 214 1555 1555 1.33 LINK C CME A 214 N LYS A 215 1555 1555 1.33 LINK C VAL A 322 N CME A 323 1555 1555 1.33 LINK C CME A 323 N LEU A 324 1555 1555 1.33 LINK C PHE A 372 N CME A 373 1555 1555 1.34 LINK C CME A 373 N SER A 374 1555 1555 1.33 LINK C LEU B 19 N CME B 20 1555 1555 1.33 LINK C CME B 20 N GLU B 21 1555 1555 1.34 LINK C GLU B 182 N CME B 183 1555 1555 1.33 LINK C CME B 183 N PRO B 184 1555 1555 1.35 LINK C PHE B 204 N CME B 205 1555 1555 1.33 LINK C CME B 205 N MET B 206 1555 1555 1.33 LINK C ASN B 213 N CME B 214 1555 1555 1.33 LINK C CME B 214 N LYS B 215 1555 1555 1.33 LINK C VAL B 322 N CME B 323 1555 1555 1.33 LINK C CME B 323 N LEU B 324 1555 1555 1.33 LINK C PHE B 372 N CME B 373 1555 1555 1.33 LINK C CME B 373 N SER B 374 1555 1555 1.33 SITE 1 AC1 6 GLY A 26 ASN A 27 LYS A 280 HOH A1024 SITE 2 AC1 6 GLY B 331 ASP B 332 CRYST1 54.115 95.047 139.225 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.018479 0.000000 0.000000 0.00000 SCALE2 0.000000 0.010521 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007183 0.00000